Literature DB >> 24090794

Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Shayla E Russell1, Anna B Rachlin1, Karen L Smith1, John Muschamp1, Loren Berry2, Zhiyang Zhao2, Elena H Chartoff3.   

Abstract

BACKGROUND: Dynorphin, an endogenous ligand at kappa opioid receptors (KORs), produces depressive-like effects and contributes to addictive behavior in male nonhuman primates and rodents. Although comorbidity of depression and addiction is greater in women than men, the role of KORs in female motivated behavior is unknown.
METHODS: In adult Sprague-Dawley rats, we used intracranial self-stimulation to measure effects of the KOR agonist (±)-trans-U-50488 methanesulfonate salt (U-50488) (.0-10.0 mg/kg) on brain stimulation reward in gonadally intact and castrated males and in females at estrous cycle stages associated with low and high estrogen levels. Pharmacokinetic studies of U-50488 in plasma and brain were conducted. Immunohistochemistry was used to identify sex-dependent expression of U-50488-induced c-Fos in brain.
RESULTS: U-50488 dose-dependently increased the frequency of stimulation (threshold) required to maintain intracranial self-stimulation responding in male and female rats, a depressive-like effect. However, females were significantly less sensitive than males to the threshold-increasing effects of U-50488, independent of estrous cycle stage in females or gonadectomy in males. Although initial plasma concentrations of U-50488 were higher in females, there were no sex differences in brain concentrations. Sex differences in U-50488-induced c-Fos activation were observed in corticotropin releasing factor-containing neurons of the paraventricular nucleus of the hypothalamus and primarily in non-corticotropin releasing factor-containing neurons of the bed nucleus of the stria terminalis.
CONCLUSIONS: These data suggest that the role of KORs in motivated behavior of rats is sex-dependent, which has important ramifications for the study and treatment of mood-related disorders, including depression and drug addiction in people.
Copyright © 2014 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  c-Fos; dynorphin; female; intracranial self-stimulation; pharmacokinetics; stress

Mesh:

Substances:

Year:  2013        PMID: 24090794      PMCID: PMC4476271          DOI: 10.1016/j.biopsych.2013.07.042

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  88 in total

1.  κ-Opioid receptors within the nucleus accumbens shell mediate pair bond maintenance.

Authors:  Shanna L Resendez; Morgan Kuhnmuench; Tarin Krzywosinski; Brandon J Aragona
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

Review 2.  Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun.

Authors:  J I Morgan; T Curran
Journal:  Annu Rev Neurosci       Date:  1991       Impact factor: 12.449

3.  The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids.

Authors:  U Arvidsson; M Riedl; S Chakrabarti; L Vulchanova; J H Lee; A H Nakano; X Lin; H H Loh; P Y Law; M W Wessendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

4.  Regulation of cocaine reward by CREB.

Authors:  W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

Review 5.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

6.  Sex difference in κ-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5'-O-(3-[35S]thiotriphosphate) binding in the guinea pig.

Authors:  Yu-Jun Wang; Khampaseuth Rasakham; Peng Huang; Darina Chudnovskaya; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2011-08-12       Impact factor: 4.030

7.  Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell.

Authors:  A L Svingos; E E Colago; V M Pickel
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

Review 8.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

9.  The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Authors:  Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

10.  Stereotyped behavior elicited by amphetamine in the rat: influences of the testes.

Authors:  W W Beatty; A M Dodge; K L Traylor
Journal:  Pharmacol Biochem Behav       Date:  1982-04       Impact factor: 3.533

View more
  46 in total

Review 1.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

2.  Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.

Authors:  E Andrew Townsend
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

Review 3.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

4.  Sex Differences in Escalated Methamphetamine Self-Administration and Altered Gene Expression Associated With Incubation of Methamphetamine Seeking.

Authors:  Atul P Daiwile; Subramaniam Jayanthi; Bruce Ladenheim; Michael T McCoy; Christie Brannock; Jennifer Schroeder; Jean Lud Cadet
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

5.  The long-term effects of stress and kappa opioid receptor activation on conditioned place aversion in male and female California mice.

Authors:  Abigail R Laman-Maharg; Tiffany Copeland; Evelyn Ordoñes Sanchez; Katharine L Campi; Brian C Trainor
Journal:  Behav Brain Res       Date:  2017-06-15       Impact factor: 3.332

6.  Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females.

Authors:  Cindee F Robles; Marissa Z McMackin; Katharine L Campi; Ian E Doig; Elizabeth Y Takahashi; Michael C Pride; Brian C Trainor
Journal:  Behav Brain Res       Date:  2014-01-18       Impact factor: 3.332

7.  Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice.

Authors:  Rachel I Anderson; Marcelo F Lopez; William C Griffin; Harold L Haun; Daniel W Bloodgood; Dipanwita Pati; Kristen M Boyt; Thomas L Kash; Howard C Becker
Journal:  Neuropsychopharmacology       Date:  2018-12-11       Impact factor: 7.853

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

9.  Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.

Authors:  Antony D Abraham; Selena S Schattauer; Kathryn L Reichard; Joshua H Cohen; Harrison M Fontaine; Allisa J Song; Salina D Johnson; Benjamin B Land; Charles Chavkin
Journal:  J Neurosci       Date:  2018-08-03       Impact factor: 6.167

10.  Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Authors:  M F Lazenka; J A Suyama; C T Bauer; M L Banks; S S Negus
Journal:  Pharmacol Biochem Behav       Date:  2016-08-24       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.